This webinar was part of the Virtual Grand Round Series titled: Addressing Unmet Needs in the Treatment of Psychiatric Disorders.

Learning Objectives

At the end of this educational activity, participants should be able to:
  • Review the epidemiology and tobacco consumption burden of psychiatric co-morbid nicotine dependence.
  • Identify evidenced based smoking cessation strategies for those with psychiatric disorders.
  • Recognize the association between varenicline and psychiatric adverse events in smokers with schizophrenia.

Target Audience

Psychiatrists, primary care/family physicians, nurses, allied healthcare professionals.


  • Director, Center for Addiction Medicine, Massachusetts General Hospital
    William Cox Family Associate Professor of Psychiatry in the Field of Addiction Medicine, Harvard Medical School

CME Information

This program is not accredited.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. CME credit is not being offered for this activity.

Credit Designation

Even though this event is not accredited, providing information regarding planning, disclosure, and conflict of interest is important to us. Some providers may be able to claim Category 2 CME credit for participating in this activity.


In accord with the guidelines of the Accreditation Council for Continuing Medical Education (ACCME), planners, speakers and anyone who may have an influence on the content of the activity have been asked to disclose any relationship they or their spouse/partner have to companies producing pharmaceuticals, medical equipment, devices, etc. that may be germane to the content of their presentation. Such disclosure is not intended to suggest or condone bias, but provides participants with information that might be of potential importance to their evaluation of a given presentation.


The MGH Academy has implemented a process to resolve potential COIs for this CME activity to help ensure content objectivity, independence, fair balance and ensure that the content is aligned with the interest of the public.

Planner Disclosure

The following planners and/or their spouse/partner have no relevant financial relationship with a commercial interest:

Tristan Gorrindo, MD: Planner

Speaker Disclosure

The following speaker and/or his spouse/partner has reported a relevant financial relationship with a commercial interest:

A. Eden Evins, MD, MPH

Research Support:

NIDA R01 DA021245 Smoking cessation and relapse prevention in schizophrenia

Pfizer: Supplemental support for the NIDA funded trial: Extended Duration Varenicline for Prevention of Smoking in Schizophrenia

NIDA R01 DA030992 Trial of an alpha-7 nicotinic agonist for nicotine dependence

Envivo Pharmaceuticals: Supplemental support for the NIDA funded Proof of Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence

NIDA U01 DA019378 Cooperative drug discovery group for nicotine dependence

GSK: Supplemental support for NIDA funded Cooperative Drug Discovery Group for Nicotine Dependence

NIDA R21 DA030808 Cognitive remediation to improve smoking outcomes

NIDA R21 DA030523 Enhancing self-control of craving with real-time fMRI

NIDA R21 DA031925 Concurrent PET D2/D3 receptor imaging and fMRI cue reactivity in smokers

NIDA K24 DA030443 Mentoring in addiction treatment research


Pfizer, DLA-Piper, Boehringer-Ingelheim


This program was originally developed as an accredited educational activity using support in the form of educational grants from the following companies:

  • Janssen Scientific Affairs, LLC
  • Lilly USA, LLC
  • Sunovion Pharmaceuticals, Inc.
  • Takeda Pharmaceutical International, Inc. and Lundbeck

Hardware/Software Specifications:

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:

Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements:

Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit